Personalis, Inc.

Healthcare · Diagnostics & Research · United States

Last price 15.925 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.70B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample....